Michael Joyce produces multimedia at HealthNewsReview.org and tweets as @mlmjoyce.
This is a unique Five Star Friday in that we have examples of great reporting from both the breaking news end of the spectrum, as well as a long-term and in-depth investigative project.
We also have two stories that scored very highly with our reviewers. This is important because the two diseases covered — Alzheimer’s disease and ulcerative colitis — are clearly in need of effective therapies.
This usually means people affected are hungry for good news. And this places a premium on covering emerging therapies for these conditions thoroughly and thoughtfully. There are readers hanging on every word.
And that is the theme running through this edition of Five Star Friday: thoroughness & thoughtfulness.
Here in Minnesota we are on the front end of what could become a major measles outbreak. But it’s not your average outbreak. It’s a dramatic story involving a tightly knit immigrant community targeted by anti-vaccine activists.
Reporter Lena Sun deftly captures the drama without being melodramatic or insensitive to those affected. There are a lot of moving parts to this story: children, fear, committed doctors frustrated by misinformation and a fraudulent doctor whose license has been revoked. It’s a compelling and informative read that digs far deeper than our local papers did.
Think investigative journalism is dead? Apparently Rosalind Adams didn’t get the memo.
After hundreds of interviews and reviewing a slew of documents, Adams paints the picture of a major chain of psychiatric hospitals filling their beds with allegedly suicidal patients — for just the right amount of time — to collect the maximum insurance payments.
Making matters worse are under-staffed facilities with inadequately trained personnel, as well as allegations of fraud and harming patients.
There is one graphic in this essay you can’t miss. It will send chills through your body.
Other than neglecting to mention the cost of this arthritis drug used to treat ulcerative colitis, health reporter Steven Reinberg does well in balancing the risks and harms of this off-label treatment. He also clearly explains the research, and even points out an important conflict of interest.
Reinberg makes it clear that this drug, tofacitinib (Xeljanz), has not been FDA-approved for treatment of ulcerative colitis.
If you know anyone who has experience with this off-label application, let us know. We’d be interested to hear about their experience.
Writing about promising new treatments for Alzheimer’s is a delicate art; especially — as in this case — when it involves a study that hasn’t even been published or presented at a scientific conference.
But Sharon Begley has the touch and — without falling into the traps of over-hyping or promising a cure-all — she writes an appropriately cautious article with this beautiful first sentence:
“A little-known drug company announced modestly encouraging results for its experimental Alzheimer’s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.”
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like